格列本脲对动脉瘤性蛛网膜下腔出血患者认知表现、生活质量及情绪方面的影响:一项随机对照试验
该随机对照试验将动脉瘤性蛛网膜下腔出血患者随机分配至格列本脲5 mg组或安慰剂组,治疗21天,起点在发病96小时内。6个月随访时,格列本脲未改善认知表现、生活质量及情绪方面,两组各项评分均无统计学显著差异。
要点
- 格列本脲组与安慰剂组6个月蒙特利尔认知评估平均分无显著差异(21.7±6.4 vs 23.4±6.2,P=0.392)。
- 认知评分<23分者共16例(35.6%),两组频率相似(P=0.900)。
- 最常受损认知域为注意力(21/45;46.7%)和视空间(18/45;40.0%),各认知域受损及平均分两组相似(P>0.05)。
核心结论
- 格列本脲未改善动脉瘤性蛛网膜下腔出血存活者6个月随访时的认知表现、生活质量和情绪方面。
研究设计与样本
- 随机对照试验,动脉瘤性蛛网膜下腔出血患者随机接受格列本脲5 mg或安慰剂治疗21天,于发病96小时内开始,6个月后评估认知表现、生活质量和情绪方面。
主要发现
- 蒙特利尔认知评估平均分为22.5±6.2,格列本脲组平均21.7±6.4 vs 安慰剂组23.4±6.2(P=0.392)。
- 认知评分<23分者16例(35.6%),两组频率相似(P=0.900)。
- 最常受损认知域为注意力(21/45;46.7%)和视空间(18/45;40.0%),各认知域受损频率及平均分两组相似(P>0.05)。
- 医院焦虑抑郁量表评分两组无差异(P>0.05)。
- 创伤后应激症状筛查平均分及其各域平均分两组相似(P>0.05)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) is associated with a high incidence of long-term cognitive impairment, decreased quality of life (QoL), and psychiatric disorders. The effects of glibenclamide on such outcomes in the setting of aSAH are unknown. OBJECTIVE: To assess the impact of glibenclamide in patients with aSAH on cognitive performance, QoL, and emotional aspects. METHODS: Patients identified with aSAH were randomly allocated to receive 5 mg of glibenclamide for 21 days or placebo, starting within 96 hours of the ictus. After 6 months, patients were evaluated with Montreal Cognitive Assessment test (cognitive performance), Medical Outcomes Short-form Health Survey (QoL), and Hospital Anxiety and Depression Scale and Screen for Post-traumatic Stress Symptoms (emotional aspects). RESULTS: The mean Montreal Cognitive Assessment score was 22.5 ± 6.2. No statistically significant difference was found between groups, with a mean score of 21.7 ± 6.4 in the Glibenclamide group and 23.4 ± 6.2 in the placebo group (P = 0.392). A score <23 was observed in 16 patients (35.6%) and its frequency was similar between groups (P = 0.900). The most frequently impaired domains were Attention (N = 21/45; 46.7%) and Visuospatial (18/45; 40.0%). Impairment of each domain was similar between groups (P > 0.05). In each domain, the mean score was similar between groups (P > 0.05). The Hospital Anxiety and Depression Scale scores did not differ between groups (P > 0.05). The mean Screen for Post-traumatic Stress Symptoms score as well as the mean scores of its domains were similar between groups (P > 0.05). CONCLUSIONS: Glibenclamide did not improve cognitive performance, QoL, and emotional aspects after 6 months of follow-up of aSAH survivors.
引用
- Windlin IC, da Costa BBS, Mota Telles JP, et al. The Effects of Glibenclamide on Cognitive Performance, Quality of Life, and Emotional Aspects Among Patients With Aneurysmal Subarachnoid Hemorrhage: A Randomized Controlled Trial. World Neurosurg. 2024. PMID: 39278541. doi:10.1016/j.wneu.2024.09.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。